CEACAM6 has been found to be highly expressed in various common cancers, including colorectal cancer [13], pancreatic duct adenocarcinoma (PDAC) [14, 15], intrahepatic cholangiocarcinoma [16], gastric cancer (GC) [10], non-small cell lung cancer (NSCLC), and head and neck squamous cell adenocarcinoma (HNSCC) [17]. Here, CEACAM6 is linked to non-small cell lung carcinoma.